British pharma major AstraZeneca's (LSE: AZN) bid to broaden the label for Tagrisso (osimertinib) will be considered under the Priority Review scheme.
The US Food and Drug Administration is set to decide by the end of the year on whether to grant a further nod for the third-generation EGFR tyrosine kinase blocker.
AstraZeneca wants to offer the drug for certain adults with unresectable non-small cell lung cancer (NSCLC), after chemoradiotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze